Quantitative Systems Pharmacology Conference
Danielle PillsburyJanuary 26, 2026
How Model-Informed Drug Development (MIDD) Strengthens Drug Asset Valuation and Answers the Questions Investors Care About Most
Learn how Model-Informed Drug Development strengthens drug asset valuation by reducing uncertainty, predicting clinical performance,…
CertaraJanuary 26, 2026
Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients
This article explores how model-based meta-analysis (MBMA) performs when combining aggregate data and individual patient…
CertaraJanuary 22, 2026
Adaptive clinical trials in oncology: Meeting the challenge of Project Optimus
Leveraging adaptive clinical trial designs in oncology can accelerate drug development, while following the FDA…
CertaraJanuary 16, 2026
Bridging the Gap: Integrating Quantitative Systems Pharmacology and Pharmacometrics in Drug Development
Quantitative Systems Pharmacology (QSP) and Pharmacometrics (PMX) have historically existed at the two ends of…
CertaraJanuary 7, 2026
